Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.

@article{Ingrand1995PhaseIS,
  title={Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.},
  author={Didier Ingrand and Jonathan Weber and Charles A. Boucher and Clive Loveday and Cheri L. Robert and Andrew Hill and Nick Cammack},
  journal={AIDS},
  year={1995},
  volume={9 12},
  pages={1323-9}
}
OBJECTIVE To evaluate the efficacy of 3TC (lamivudine), a synthetic nucleoside analogue that inhibits HIV reverse transcriptase in vitro, as treatment for HIV-positive, asymptomatic or mild AIDS-related complex patients. DESIGN Open-label, multinational and multicentre, non-comparative, escalating dose study. METHODS Patients who meet the selection criteria (n = 104) were enrolled in three European countries. Ten to 15 patients were included at each of the six dose levels of 3TC (0.5, 1.0… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…